Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index
December 21 2020 - 09:27AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that it has been selected for inclusion in the NASDAQ Biotechnology
Index (Nasdaq: NBI), based on the results of the annual
reconstitution of the index announced by Nasdaq on December 11,
2020. The inclusion will become effective prior to the U.S. market
open on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on the NASDAQ Stock
Market that are classified as either biotechnology or
pharmaceutical companies, and is a modified market capitalization
weighted index. According to NASDAQ, the NBI is reconstituted
annually in December in accordance with a set of eligibility
criteria including minimum market capitalization and average daily
trading volume. The index currently has 198 securities as its
components. For more information about the NBI, please visit
https://indexes.nasdaqomx.com/index/overview/nbi.
About Arcutis - Bioscience,
applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is
a late-stage biopharmaceutical company focused on developing and
commercializing treatments for unmet needs in immune-mediated
dermatological diseases and conditions, or immuno-dermatology. The
company is leveraging recent advances in immunology and
inflammation to develop differentiated therapies against
biologically validated targets to solve persistent treatment
challenges in serious diseases of the skin. Arcutis’ robust
pipeline includes four novel drug candidates currently in
development for a range of inflammatory dermatological conditions.
The company’s lead product candidate, topical roflumilast, has the
potential to revitalize the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For
more information, visit www.arcutis.com or follow the company on
LinkedIn and Twitter.
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2023 to Mar 2024